Position of the Transparency Council – Balversa (erdafitinib)
At its meeting on 5 May 2025, the Transparency Council adopted position No. 51/2025 on the evaluation of the medicinal product Balversa (erdafitinib) for the indication: “Treatment of patients with urothelial cancer (ICD-10: C61, C65, C66, C67, C68)”.